Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company historically focused on developing and commercializing prescription therapies for women’s health. The company operated primarily within the biopharmaceutical and women’s healthcare industries, with an emphasis on hormone-based treatments addressing menopause-related conditions. Its core products targeted vasomotor symptoms and dyspareunia associated with menopause, and revenues were historically derived from branded prescription drug sales in the United States.
The company was founded in 2008 and pursued a strategy of building a women’s health–focused pharmaceutical platform through internal development and regulatory approval of proprietary drug formulations. Over time, TherapeuticsMD faced commercialization and capital structure challenges, which led to significant strategic changes. Between 2022 and 2023, the company divested substantially all of its operating assets and transitioned away from active pharmaceutical operations. As of the most recent public disclosures, TherapeuticsMD no longer markets prescription products and is evaluating strategic alternatives. Data regarding long-term operating plans is inconclusive based on available public sources.
Business Operations
Historically, TherapeuticsMD generated revenue through the commercialization of its FDA-approved women’s health products, including IMVEXXY, BIJUVA, and ANNOVERA, which were sold to healthcare providers and distributed through U.S. pharmaceutical channels. Operations were primarily domestic, with commercialization focused on the United States market. The company did not maintain large-scale international sales operations prior to asset divestitures.
Following the sale of its commercial portfolio, TherapeuticsMD no longer operates active business segments or revenue-generating units. The company retains a public corporate structure but has minimal ongoing operations. Any remaining activities are primarily related to corporate governance, regulatory compliance, and the management of residual assets and liabilities. Information regarding new operating segments or revenue sources cannot be verified based on current public filings.
Strategic Position & Investments
TherapeuticsMD’s historical strategy centered on becoming a leading pure-play women’s health pharmaceutical company through internally developed hormone therapies. This strategy shifted materially when the company sold ANNOVERA to Mayne Pharma Group Limited and later divested IMVEXXY and BIJUVA to Mayne Pharma as well, effectively exiting commercial operations. These transactions represented a strategic pivot driven by balance sheet constraints and the need to reduce operating losses.
As of the most recent disclosures, the company does not report active growth initiatives, operating investments, or control of notable subsidiaries or portfolio companies. TherapeuticsMD has indicated that it is evaluating strategic alternatives, which may include mergers, asset acquisitions, or other corporate transactions; however, no definitive strategic direction has been publicly confirmed. Data inconclusive based on available public sources.
Geographic Footprint
Historically, TherapeuticsMD’s operational footprint was concentrated in the United States, where it maintained its headquarters and conducted all commercial activities. Product sales, marketing, and regulatory operations were U.S.-focused, with no material revenue contribution from international markets prior to asset sales.
Following the divestiture of its operating assets, the company no longer maintains a meaningful geographic operating presence beyond its corporate headquarters in the United States. Any international exposure through licensing, distribution, or investment activities cannot be substantiated by current public disclosures.
Leadership & Governance
TherapeuticsMD was founded by Robert G. Finizio, who played a central role in shaping the company’s original women’s health–focused strategy. Leadership historically emphasized the development of FDA-approved, bio-identical hormone therapies and building a specialized commercial infrastructure in women’s healthcare. Governance has been overseen by a publicly traded board of directors subject to U.S. securities regulations.
Key executives disclosed in recent public filings include:
- John D. Rapisardi – Chief Executive Officer
- Daniel A. Swisher – Chief Financial Officer
- Robert G. Finizio – Founder and former Chief Executive Officer
Leadership’s current strategic vision centers on corporate restructuring and the evaluation of strategic alternatives rather than operational expansion. Specific long-term governance or operational objectives beyond this mandate are not clearly defined in publicly available information.